



Transforming cancer care through direct alpha therapy

Øystein Soug, CEO

21 September 2026 · Euronext Oslo: ONCIN



Disclaimer and important information



This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company in any jurisdiction. Any securities of the Company may not be offered or sold except pursuant to applicable law and in accordance with applicable registration requirements or exemptions therefrom.

This Presentation is not intended to be, and should not be construed as, legal, tax, investment or other advice. Recipients should consult their own advisers as to the legal, tax, financial, investment and other matters contained herein. By attending a meeting where this Presentation is made and/or by reading these materials, you acknowledge that you are solely responsible for your own assessment of the Company and the information contained in this Presentation.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information contained in this Presentation. Certain information in this Presentation has not been independently verified. The information contained herein is subject to change without notice and the Company does not undertake any obligation to update or revise this Presentation, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Presentation contains forward-looking statements, including, without limitation, statements regarding the Company’s strategy, plans, objectives, milestones, clinical development activities, timelines, trial design and outcomes, regulatory interactions, manufacturing and supply chain readiness, partnering intentions, market opportunity, and expected financial performance and cash runway. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the inherent uncertainty in drug development; the ability to initiate, conduct and complete preclinical and clinical studies and obtain expected data within anticipated timelines; patient recruitment and retention; clinical trial site activation and operational execution; safety, tolerability and efficacy outcomes; regulatory review, communications and approvals; changes in applicable laws, regulations and regulatory guidance; manufacturing, quality and supply chain risks (including availability of radionuclides, production capacity, validation and compliance with GMP requirements); reliance on third parties and suppliers; intellectual property protection and freedom to operate; competitive developments; the ability to obtain, maintain and enforce patents and other rights; the ability to enter into and maintain collaborations and partnerships on acceptable terms; pricing, reimbursement and market adoption; and the Company’s ability to raise additional financing when needed. Additional risks and uncertainties are described in the Company’s publicly available disclosures from time to time.


Nothing in this Presentation is intended to be, or should be construed as, medical advice, a diagnosis, or a recommendation regarding any treatment. Any product candidates referenced are investigational and have not been approved for marketing by any regulatory authority, and their safety and efficacy have not been established.

Certain financial and other measures included in this Presentation may not be prepared in accordance with IFRS and may be alternative performance measures (“APMs”). Such measures may not be comparable to similarly titled measures presented by other companies. Definitions and reconciliations, if any, should be read together with the Company’s financial reporting.

The distribution of this Presentation may be restricted by law in certain jurisdictions, and persons into whose possession it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.


This Presentation speaks as of 21 September 2026. The Company undertakes no obligation to update it except as required by applicable law.

Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy




Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options

Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy



Micrometastases

Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options




Oncoinvent develops Radspherin®, a receptor-independent alpha radiopharmaceutical that **eradicates cancer cells in the abdominal cavity after surgery** with a single, targeted dose.

Radspherin[®], peritoneal-targeted alpha therapy


A single dose through an in-dwelling catheter kills metastases and spares normal tissue

Radspherin[®]

- Combining **alpha-emitting ^{224}Ra** with **CaCO_3** microparticles
- Half-life 3.6 days
- **Therapy with depot effect** - 75% of radiation dose delivered the first week
- Shelf-life 8 days allowing for **centralized manufacturing**
- Good **raw material availability** and simple manufacturing



Radspherin® addresses a large high-risk patient population with no effective treatment option



Radiopharmaceutical excellence: expertise across the spectrum



Scientific founders



Roy Larsen



Øyvind Bruland



Team



Oystein Soug
Chief Executive Officer



Gro Hjellum
Chief Operations Officer



Ramzi Amri
Chief Financial Officer



Kari Myren
Chief Medical Officer



Anne-Kirsti Aksnes
Chief Clinical Officer



Kristine Lofthus
Chief Production Officer



Sara Westrøm
Chief Scientific Officer



Board



Gillies O'Bryan-Tear
Chair



Kari Grønås



Hilde Steineger



Ingrid Teigland Akay



Orlando Oliveira




Johan Häggblad




Anne Cecilie Alvik



Olav Hellebo



Ovarian cancer focus, same drug leveraged into CRC



Ovarian Phase 1: recurrence was rarely peritoneal at 24 months

Final 24-month follow-up | 10 patients at the recommended 7 MBq dose


10%

peritoneal recurrence

1 of 10 patients at 24 months

Overall recurrence rate

Radspherin® (RAD-18-001, n=10)



+ two lymph-node recurrences (typically better prognosis than peritoneal relapse)

Historical benchmark*



“These final results are truly encouraging, suggesting that Radspherin® could help delay disease progression and offer patients hope for longer, healthier lives. It is particularly promising to see that the new recurrences were limited to lymph nodes, which are typically associated with longer survival compared to peritoneal relapses.”

Dr Luis Chiva, Principal Investigator; Director, Dept. of Obstetrics & Gynecology, Clínica Universidad de Navarra, Spain

Single-arm Phase 1 (n=10 at 7 MBq)

* Historical benchmark reports overall recurrence only, with no peritoneal breakdown

Colorectal Phase 1/2a: the same compartment-level signal, a second tumor



Final 18-month follow-up | 36 patients at the recommended 7 MBq dose

Peritoneal recurrence rate · Radspherin® vs a literature benchmark (same endpoint)

Radspherin® (n=36, 7 MBq)

28%


peritoneal recurrence



Literature benchmark*

~50%

peritoneal recurrence



“It's highly encouraging to see patients treated with Radspherin achieving outcomes that exceed expectations for this challenging population. As a clinician, I'm hopeful that this promising therapy will become an option I can offer to future patients in need.”

Dr. Stein Gunnar Larsen, Principal Investigator, Oslo University Hospital, Norway

Randomized Phase 2 study in first-line treatment of ovarian cancer

Patient population

- primary advanced ovarian cancer
- undergoing neoadjuvant chemotherapy and interval debulking surgery
- eligible for complete resection
- HRD negative



10 active study sites:
NO, BE, ES (4), UK(2), IT, USA



Long-term follow-up
for up to 5 years for
progression and
survival



Patient recruitment momentum continues to accelerate

Patients recruited, incl. safety run-in



Patients recruited

55

To date, crossed halfway point

Active sites

10

Four new sites added in 1H26

Q2 2026 recruitment


18

Best quarter to date

H1 2026 recruitment

29

More than full year 2025



Looking ahead: preparing for Phase 3



Regulatory dialogue

Early engagement with regulators, making full use of the fast-track designation



Study design

Phase 3 study design and protocol validation in progress



Manufacturing readiness

Scaling production capacity and progressing CDMO selection and tech transfer readiness



Partnering

Preparing for partnerships and strategic collaborations

Early efficacy and safety signals, a platform mechanism, and a team that has done it before



High unmet medical need from cancers in the peritoneum

- No approved drugs or product aimed specifically at prevention of local peritoneal disease recurrence beyond HIPEC
- Fast track designation in OC with blockbuster potential in this indication alone



Clear efficacy signals

- In Ovarian Cancer (Ph1) 90% remain without peritoneal recurrence after 24 months
- In Colorectal cancer (Ph1/2a) 72% remained without peritoneal recurrence after 18 months



Strong safety profile, with localized administration limiting systemic exposure

- No dose-limiting toxicity, few side-effects
- In 68 patients, only 3 SAEs deemed “possibly related” to Radspherin[®]*, with limited temporal or procedural association



Unique mode of action, lower complexity with platform potential

- Same product, same approach, same process for **any cancer with peritoneal spread**
- MoA is **effective for any tumor cell**, regardless of origin or mutation profile



Experienced team with a track record

- Founded by a team with **decades of experience in radiopharma**, including **developing the first approved alpha therapy**
- Operate **own GMP facility** with unique knowhow

*Per data-lock June 2025: one event of small bowel perforation, 72 days after Radspherin administration; one event of intestinal obstruction, 531 days after administration; one event of procedural complication during Radspherin administration (disconnection syringe-catheter)